Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Baricitinib in Healthy Chinese Subjects
NCT02758613Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2016
- Primary completion
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of baricitinib in rheumatoid arthritis (RA) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Clinically Significant Event(s) at Day 20. Started May 2016; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02758613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02758613.